研究人员发现了败血症及其相关感染的可能治疗方法原创 2016-05-08 SIFIC热点团队 SIFIC官微
研究人员发现了败血症及其相关感染的可能治疗方法Researchers Discover Potential Treatment for Sepsis and Other Responses to Infection
检索：陈燕琼 暨南大学附属东莞市第五人民医院
翻译：陈燕琼 暨南大学附属东莞市第五人民医院 审核：陈志锦 广东医科大学附属东莞市厚街医院
Researchers at the Icahn School of Medicine at Mount Sinai say that tiny doses of a cancer drug may stop the raging, uncontrollable immune response to infection that leads to sepsis and kills up to 500,000 people a year in theU.S.The new drug treatment may also benefit millions of people worldwide who are affected by infections and pandemics. 西奈山伊坎医学院的研究员说，小剂量的抗癌药物将可能阻止由感染引起的无法控制的免疫反应的肆虐，其导致的败血症每年在美国引起超过500000人死亡。这种新药物治疗也可能给全世界数百万受感染折磨的人带来福音。
Their study reported in Science, demonstrates in both cells and animals that a small dose of topoisomerase I (Top 1) inhibitor can dampen an acute inflammatory reaction to infection while still allowing the body's protective defense to take place. The title of the study is "Topoisomerase 1 inhibition suppresses the transcriptional activation of innate immune responses and protects against inflammation-induced death." 他们的研究发表在《科学》杂志上，论证了同时在细胞和动物里小剂量的拓扑异构酶I(Top 1)抑制剂能够抑制感染的急性炎症反应，同时还能让体内的保护性防御机制继续运行。这项研究的主题是“拓扑异构酶I(Top 1)抑制剂抑制先天免疫反应的转录激活，从而防止炎症引起的死亡”
The treatment may help control not only sepsis -- deadly infections often acquired in hospital by patients with a weak immune system -- but also new and brutal assaults on human immunity such as novel influenza strains and pandemics of Ebola and other singular infections, says the study's senior investigator, Ivan Marazzi, PhD, an assistant professor of microbiology at the Icahn School of Medicine at Mount Sinai. 本研究的高级研究员——西奈山伊坎医学院助理微生物教授伊凡马齐儿博士说，这项治疗不仅可以帮助控制败血症，还可以帮助由于免疫力低下而容易获得致命医院感染的患者。尽管如此，人类的免疫系统也正面临着新的残酷挑战，例如新型流感毒株、埃博拉病毒和其他罕见的感染。
"Our results suggest that a therapy based on Top 1 inhibition could save millions of people affected by sepsis, pandemics, and many congenital deficiencies associated with acute inflammatory episodes -- what is known as a cytokine, or inflammatory, storm," says Marazzi. 马齐儿博士说：“我们的研究结果表明，基于Top 1抑制的治疗可以数以万计受败血症、传染病和许多急性炎症发作相关先天免疫缺陷的人，这被称为细胞因子风暴。
"These storms occur because the body does not know how to adjust the appropriate level of inflammation that is good enough to suppress an infection but doesn't harm the body itself," he says. "This drug appears to offer that life-saving correction." 他接着说：“这些细胞因子风暴的发生，是因为身体不知道如何调节适当的炎症水平，能够足以抑制感染但又不至于伤害到身体，这种药似乎能为身体的这种调节作出修正。”
Sepsis is caused by an excessive host response to infection, which in turn leads to multiple organ failure and death. With an overall mortality rate between 20 and 50%, sepsis is the tenth leading cause of death in theU.S.-- it kills more people than do HIV and breast cancer. 败血症是由于宿主对感染的过度免疫反应引起的，而且会导致多器官功能衰竭甚至死亡。败血症的总体死亡率在20-50%之间，是美国排名第十的死亡原因，死亡人数比HIV感染和乳腺癌还要多。
"To date there has been no targeted treatment for sepsis, or for other infections that promote this inflammatory storm," says Marazzi. "Such treatment is desperately needed." 马齐儿博士接着说：“到目前为止，还没有败血症或者炎症因子风暴介导感染的针对性治疗方法，但是这种治疗又是迫切需要的。”
The Mount Sinai team found that use of one to three doses of a Top 1 inhibitor that is 1/50th the strength of normal chemotherapy was enough to rescue 70 percent to 90 percent of mice from an inflammatory storm death due to either acute bacterial infection, liver failure, or virus-bacteria co-infection. The treatment did not produce overt side effects. 西奈山医学院研究小组发现，使用一到三份Top 1抑制剂就相当于1/50普通化疗药物的药效，足够拯救70%~90%因炎症因子风暴之死的病鼠，无论是由于急性细菌感染、肝衰竭，还是因为病毒细菌混合感染。而且这种治疗方法没有产生明显的副作用。
"We observed a striking effect of Top-1 inhibitors on expression of pro-inflammatory molecules induced by Ebola virus infection. This study contributes our understanding of pathogenesis of Ebola virus disease and also suggests a direction to develop treatments," says Alexander Bukreyev, PhD, professor in the Department of Pathology and Microbiology & Immunology at the Galveston National Laboratory at the University of Texas Medical Branch. 德克萨斯医科大学加尔维斯顿国家实验室的病理学与微生物学教授，亚历山大布克列耶夫博士说：“我们观察到，TOP1-1对埃博拉病毒感染的促炎因子有显著抑制效果，这项研究我们了解埃博拉出血热的发病机制，同时也为治疗指明了方向。
"Finding remedies for these infection-induced inflammatory storms is a global focus, and we look forward to testing the ability of Top-1 inhibitors to save lives," adds Marazzi. 马齐儿博士补充道：“为因炎症因子风暴引起的感染寻找治疗方法是全球重点问题，我们期待着Top-1抑制剂挽救生命的可靠性。”
Mount Sinai has filed a patent application for using a Top-1 inhibitor in sepsis and other inflammatory conditions. 西奈山伊坎医学院已经就使用Top 1抑制剂治疗败血症和其他炎症疾病申请了专利。 Source: Mount Sinai Health System资料来源：西奈山医疗系统
摘自： http://www.infectioncontroltoday.com/news/2016/04/researchers-discover-potential-treatment-for-sepsis-and-other-responses-to-infection.aspx
| 
/1 
IP卡
狗仔卡
发表于 2016-5-26 23:34:04
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
抢沙发
千斤顶
显身卡
发表于 2017-2-3 22:06:53